Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Allergy and Immunology

Standard of Care and Treatment Options

At a Glance

Treatment for non-histaminic angioedema requires specialized medications because standard allergy drugs like antihistamines and epinephrine are ineffective. Management focuses on discontinuing ACE inhibitors if they are the cause, or using targeted on-demand and preventive therapies for hereditary forms.

The goal of treatment for non-histaminic angioedema (NHA) shifts from “hoping it doesn’t happen” to a strategy of total control.

The Rule of “Ineffective Three”

Antihistamines, corticosteroids (like prednisone), and epinephrine (EpiPens) do not work for bradykinin-mediated swelling [1][2]. If you have non-histaminic angioedema, you need a different toolkit.

Managing ACE-Inhibitor Induced Angioedema

If your swelling is caused by a blood pressure medication (an ACE inhibitor), the primary treatment is to permanently stop the drug [3]. Crucial Distinction: Unlike HAE patients, patients with ACE-inhibitor-induced swelling typically do not need to carry on-demand rescue medications once the offending drug is stopped and the lingering risk period (weeks to months) has passed. The most important step is airway management during an active attack and switching to a different class of blood pressure medication [4][5].

Hereditary Angioedema: Acute (On-Demand) Treatments

Patients diagnosed with Hereditary Angioedema (HAE) require specialized “on-demand” medications to stop an attack from progressing [6][7].

  • C1-Inhibitor Concentrates: These replace the missing “brake” in your body [8][6]. They can often be self-administered at home after training.
  • Icatibant: A small injection that blocks the B2 receptor, effectively putting a cap on the “leak” [6][9]. It can also be self-administered.
  • Ecallantide: This medication inhibits kallikrein [6][10]. Safety Note: Ecallantide carries a black-box warning for anaphylaxis and cannot be self-administered at home. It must be given by a healthcare professional in a medical setting.

Hereditary Angioedema: Long-Term Prophylaxis

For frequent attacks, your doctor may recommend long-term prophylaxis (LTP). Modern guidelines advocate for a Treat-to-Target approach aiming for zero attacks [11][12].

  • Targeted Biologics: Lanadelumab (an injection) and Berotralstat (a daily oral pill) keep the bradykinin-producing enzymes in a “rest” state [13][14].
  • Traditional Therapies: While biologics are the modern standard, older therapies like attenuated androgens (e.g., Danazol) or antifibrinolytics (e.g., Tranexamic acid) are still used by some international patients or those navigating insurance barriers.

Common questions in this guide

Why don't antihistamines and EpiPens work for my swelling?
Standard allergy medications like antihistamines, corticosteroids, and epinephrine are ineffective because your swelling is driven by a substance called bradykinin, not histamine. You will need specialized medications designed to target bradykinin.
How is ACE-inhibitor induced angioedema treated?
The most important step is to permanently stop taking the ACE inhibitor and switch to a different class of blood pressure medication. Once the drug is out of your system and the risk period has passed, you typically do not need to carry on-demand rescue medications.
What on-demand medications are used for hereditary angioedema (HAE)?
To stop an active attack, doctors prescribe specialized medications like C1-inhibitor concentrates, icatibant, or ecallantide. Many of these can be self-administered at home after proper training, except for ecallantide, which must be given in a medical setting.
What is the goal of long-term prevention for HAE?
Modern guidelines recommend a 'Treat-to-Target' approach, which aims for zero swelling attacks. This is often achieved using targeted biologic medications that keep bradykinin-producing enzymes at rest.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since I have non-histaminic angioedema, what specific on-demand medication should I have on hand for an acute attack, if any?
  2. 2.Can we implement a 'Treat-to-Target' strategy to aim for zero attacks and a normal quality of life?
  3. 3.If I am taking an ACE inhibitor, what alternative blood pressure medication is safest for me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature.

    Brown T, Gonzalez J, Monteleone C

    Journal of clinical hypertension (Greenwich, Conn.) 2017; (19(12)):1377-1382 doi:10.1111/jch.13097.

    PMID: 28994183
  2. 2

    ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients.

    Weisman DS, Arnouk N, Asghar MB, et al.

    Journal of community hospital internal medicine perspectives 2020; (10(1)):16-18 doi:10.1080/20009666.2020.1711641.

    PMID: 32128053
  3. 3

    Angioedema.

    Lacuesta G, Betschel SD, Tsai E, Kim H

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2024; (20(Suppl 3)):65 doi:10.1186/s13223-024-00934-3.

    PMID: 39654054
  4. 4

    Barely There But Existent: Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.

    Butt MA, Kumar S, Sarwer SM, Manna D

    Cureus 2025; (17(10)):e94104 doi:10.7759/cureus.94104.

    PMID: 41209890
  5. 5

    Isolated Laryngeal Angioedema in a Patient with Long-term ACE Inhibitor Use: A Case Report.

    Flinn C, Massaro I

    Clinical practice and cases in emergency medicine 2024; (8(1)):18-21 doi:10.5811/cpcem.1565.

    PMID: 38546304
  6. 6

    Acute Management of Hereditary Angioedema Attacks.

    Katelaris CH

    Immunology and allergy clinics of North America 2017; (37(3)):541-556 doi:10.1016/j.iac.2017.04.002.

    PMID: 28687108
  7. 7

    Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review.

    Craig TJ, Schneider LC, MacGinnitie AJ

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2015; (26(6)):537-44 doi:10.1111/pai.12425.

    PMID: 26111105
  8. 8

    Hereditary angioedema: how to approach it at the emergency department?

    Serpa FS, Mansour E, Aun MV, et al.

    Einstein (Sao Paulo, Brazil) 2021; (19()):eRW5498 doi:10.31744/einstein_journal/2021RW5498.

    PMID: 33852678
  9. 9

    Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).

    Wedner HJ

    Allergy and asthma proceedings 2020; (41(Suppl 1)):S14-S17 doi:10.2500/aap.2020.41.200081.

    PMID: 33109319
  10. 10

    The future of therapeutic options for hereditary angioedema.

    Smith TD, Riedl MA

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024; (133(4)):380-390 doi:10.1016/j.anai.2024.04.029.

    PMID: 38679158
  11. 11

    A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.

    Cancian M, Caballero T, Boccon-Gibod I, et al.

    Frontiers in immunology 2026; (17()):1773279 doi:10.3389/fimmu.2026.1773279.

    PMID: 41766887
  12. 12

    Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment.

    Villa KF, Mansfield C, Yarlas A, et al.

    The patient 2026; (19(3)):481-495 doi:10.1007/s40271-025-00798-8.

    PMID: 41565919
  13. 13

    A review of kallikrein inhibitor lanadelumab in hereditary angioedema.

    Hwang G, Johri A, Ng S, Craig T

    Immunotherapy 2019; (11(11)):937-944 doi:10.2217/imt-2018-0197.

    PMID: 31234673
  14. 14

    A review of berotralstat for the treatment of hereditary angioedema.

    Farkas H, Balla Z

    Expert review of clinical immunology 2023; (19(2)):145-153 doi:10.1080/1744666X.2023.2150611.

    PMID: 36408587

This page is for informational purposes only and does not replace professional medical advice. Always consult your allergist or immunologist to determine the safest and most effective treatment plan for your specific type of angioedema.

Get notified when new evidence is published on Non-histaminic angioedema.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.